MedTrace Logo

Retrospective Trial on the Efficacy and Safety of Intravitreal Ozurdex in Patients With Diabetic Macular Edema.

NCT02121197 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 321

Last updated 2018-05-21

No results posted yet for this study

Summary

To review the safety and efficacy of injections with Ozurdex (700 μg dexamethasone) in clinical practice management of patients with DME.

Conditions

Interventions

DRUG

Ozurdex

Sponsors & Collaborators

  • European Vision Institute Clinical Research Network

    collaborator NETWORK

  • Association for Innovation and Biomedical Research on Light and Image

    lead OTHER

Principal Investigators

  • Anat Loewenstein, Professor · Tel-Aviv Sourasky Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-31
Primary Completion
2016-01-31
Completion
2016-01-31

Countries

  • Finland
  • France
  • Israel
  • Italy
  • Portugal
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02121197 on ClinicalTrials.gov